Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A novel retinoblastoma therapy from genomic and epigenetic analyses.

Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, Mardis ER, Bahrami A, Ellison D, Wilson RK, Downing JR, Dyer MA.

Nature. 2012 Jan 11;481(7381):329-34. doi: 10.1038/nature10733.

2.

RB1 gene inactivation by chromothripsis in human retinoblastoma.

McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, Mullighan C, Song G, Chen X, Wilson M, Brennan R, Pounds S, Becksfort J, Huether R, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Mardis ER, Wilson RK, Easton J, Zhang J, Downing JR, Ganguly A, Dyer MA.

Oncotarget. 2014 Jan 30;5(2):438-50.

3.

Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, Pang R, Massey C, Godbout R, Jiang Z, Zacksenhaus E, Paton K, Moll AC, Houdayer C, Raizis A, Halliday W, Lam WL, Boutros PC, Lohmann D, Dorsman JC, Gallie BL.

Lancet Oncol. 2013 Apr;14(4):327-34. doi: 10.1016/S1470-2045(13)70045-7.

4.

Cross-species genomic and epigenomic landscape of retinoblastoma.

Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, Wang YD, Neale G, Ragsdale S, Valentine V, Bahrami A, Temirov J, Pounds S, Zhang J, Dyer MA.

Oncotarget. 2013 Jun;4(6):844-59.

5.

Genetics and epigenetics of human retinoblastoma.

Benavente CA, Dyer MA.

Annu Rev Pathol. 2015;10:547-62. doi: 10.1146/annurev-pathol-012414-040259. Review.

PMID:
25621664
6.

Time-course gene profiling and networks in demethylated retinoblastoma cell line.

Malusa F, Taranta M, Zaki N, Cinti C, Capobianco E.

Oncotarget. 2015 Sep 15;6(27):23688-707.

7.

SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells.

Qiu Q, Yang C, Xiong W, Tahiri H, Payeur M, Superstein R, Carret AS, Hamel P, Ellezam B, Martin B, Vezina M, Sapieha P, Liu G, Hardy P.

Apoptosis. 2015 Dec;20(12):1613-22. doi: 10.1007/s10495-015-1177-2.

PMID:
26404525
8.

Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.

Pritchard EM, Stewart E, Zhu F, Bradley C, Griffiths L, Yang L, Suryadevara PK, Zhang J, Freeman BB 3rd, Guy RK, Dyer MA.

Pharm Res. 2014 Nov;31(11):3060-72. doi: 10.1007/s11095-014-1399-y.

9.

Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Pritchard EM, Dyer MA, Guy RK.

Mini Rev Med Chem. 2016;16(6):430-54. Review.

PMID:
26202204
10.

The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion.

Dehainault C, Garancher A, Castéra L, Cassoux N, Aerts I, Doz F, Desjardins L, Lumbroso L, Montes de Oca R, Almouzni G, Stoppa-Lyonnet D, Pouponnot C, Gauthier-Villars M, Houdayer C.

Hum Mol Genet. 2014 Oct 1;23(19):5243-50. doi: 10.1093/hmg/ddu245.

PMID:
24858910
11.

Genetic and Epigenetic Discoveries in Human Retinoblastoma.

McEvoy JD, Dyer MA.

Crit Rev Oncog. 2015;20(3-4):217-25. Review.

PMID:
26349417
12.

The Rb1 gene inhibits the viability of retinoblastoma cells by regulating homologous recombination.

Yang Y, Tian S, Brown B, Chen P, Hu H, Xia L, Zhang J, Cai X, Chen Z, Pan X, Ge J, Yu K, Zhuang J.

Int J Mol Med. 2013 Jul;32(1):137-43. doi: 10.3892/ijmm.2013.1374.

PMID:
23670186
13.

Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression.

Kooi IE, Mol BM, Moll AC, van der Valk P, de Jong MC, de Graaf P, van Mil SE, Schouten-van Meeteren AY, Meijers-Heijboer H, Kaspers GL, Te Riele H, Cloos J, Dorsman JC.

EBioMedicine. 2015 Jul 8;2(7):660-70. doi: 10.1016/j.ebiom.2015.06.022.

14.

Rb suppresses human cone-precursor-derived retinoblastoma tumours.

Xu XL, Singh HP, Wang L, Qi DL, Poulos BK, Abramson DH, Jhanwar SC, Cobrinik D.

Nature. 2014 Oct 16;514(7522):385-8. doi: 10.1038/nature13813.

15.

Getting Syk: spleen tyrosine kinase as a therapeutic target.

Geahlen RL.

Trends Pharmacol Sci. 2014 Aug;35(8):414-22. doi: 10.1016/j.tips.2014.05.007. Review.

16.

Inactivation of the p53 pathway in retinoblastoma.

Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA.

Nature. 2006 Nov 2;444(7115):61-6.

PMID:
17080083
17.

Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing.

Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM, Bolivar J, Gutierrez-Aviño FJ, Dominguez M.

Nature. 2006 Jan 26;439(7075):430-6.

PMID:
16437107
18.

Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.

Xie C, Lu H, Nomura A, Hanse EA, Forster CL, Parker JB, Linden MA, Karasch C, Hallstrom TC.

Mol Cancer. 2015 Apr 24;14:93. doi: 10.1186/s12943-015-0360-y.

19.

Uncommon RB1 somatic mutations in a unilateral retinoblastoma patient.

Ottaviani D, Alonso C, Szijan I.

Medicina (B Aires). 2015;75(3):137-41.

20.

Genomics: The path to retinoblastoma.

Sage J, Cleary ML.

Nature. 2012 Jan 18;481(7381):269-70. doi: 10.1038/481269a. No abstract available.

PMID:
22258599
Items per page

Supplemental Content

Support Center